The Utility of 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography in the Investigation of Patients with Disseminated Carcinoma of Unknown Primary Origin

Scott, Clare L.; Kudaba, Iveta; Stewart, Josephine; Hicks, Rodney J.; Rischin, Danny

doi:10.1007/s11307-005-4114-x

Cited by 23 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another explanation is that the primary lesion has involuted and is not detectable when the metastasis becomes evident [22,23]. According to the studies of 18 F-FDG PET/CT in CUP, the detection rates of PET/CT were from 24 to 80 percent with large differences between studies [8][9][10][11][12]. Results of this study show the detection rate of 9.6 % which is much lower than the results of previous studies.…”

Section: Discussionmentioning

confidence: 55%

See 1 more Smart Citation

Clinical implication of 18F-FDG PET/CT in carcinoma of unknown primary

Sj²,

Ij³

et al. 2011

neo

View full text Add to dashboard Cite

The value of 18 F-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in the detection of carcinoma of unknown primary (CUP) differs among the studies. This study aimed to evaluate the role of 18 F-FDG PET/CT in CUP.Fifty-one patients (19 women, 32 men) with metastasis confirmed by histopathology from an unknown primary tumor were included in this study. Patients received 370 MBq of 18 F-FDG intravenously, and PET/CT was performed at 60 minutes after injection.Primary tumor sites were detected in 5 of 51 patients (9.6%): in 2 patients with carcinoma of the lung, in 1 patient with carcinoma of the gallbladder, in 1 patient with carcinoma of the esophagus, and in 1 patient with carcinoma of the stomach. No primary tumor was discovered in the remaining 46 patients (90.4%) during the follow-up. The sensitivity, specificity, and accuracy of 18 F-FDG PET/CT were 100%, 80.4%, and 82.4%. The positive and negative predictive values were 35.7 and 100%, respectively.Based on the data presented, 18F-FDG PET/CT has a clinical implicative value in detecting the primary tumor of CUP. PET/CT can be useful to rule out the possibility of detecting the primary tumor during the follow-up.

show abstract

Section: Discussionmentioning

confidence: 55%

“…Studies have shown that positron emission tomography/ computed tomography (PET/CT) utilizing 18 F-Fluorodeoxyglucose (FDG) is a valuable tool in patients with CUP, but with large difference between studies from 24 to 80 percent of detection rates [8][9][10][11][12].…”

mentioning

confidence: 99%

Clinical implication of 18F-FDG PET/CT in carcinoma of unknown primary

Sj²,

Ij³

et al. 2011

neo

View full text Add to dashboard Cite

show abstract

“…The minimally invasive diagnostic procedure, 18 Ffluorodeoxyglucose positron emission tomography, could prove helpful for the detection of disseminated tumors. 12 Preoperative chemoradiotherapy using GEM has been reported to contribute to the improved survival of patients with pancreatic cancer; 13,14 however, we could not find any other report of successful neoadjuvant chemotherapy with GEM alone making R0 resection of stage IVB pancreatic cancer possible. Our patient's condition has remained satisfactory, and he has been free of symptoms for more than 40 months since the initial treatment.…”

Section: Discussionmentioning

confidence: 71%

Successful Resection of Advanced Pancreatic Tail Cancer After Neoadjuvant Gemcitabine Chemotherapy: Report of a Case

Matsuda¹,

Taniguchi

Minato³

et al. 2006

Surg Today

View full text Add to dashboard Cite

Pancreatic cancer with distant metastasis is not an indication for surgery, and the median survival of these patients is less than 3 months. We report the case of a patient who has survived for 21 months without any signs of recurrence after resection of advanced pancreatic cancer following a course of chemotherapy with gemcitabine (GEM). A 75-year-old man was hospitalized for anorexia and emaciation. Examinations showed pancreatic cancer with distant peritoneal metastasis. After the main tumor and metastasis had been shrunk by GEM chemotherapy, we performed distal pancreatectomy combined with splenectomy. Microscopically, the main tumor was confirmed as moderately differentiated tubular adenocarcinoma with interstitium and fibrosis. The radicality of the surgery was R0, according to the TNM classification of the UICC. The patient recovered well and has had no clinical symptoms for 40 months since the initial chemotherapy. This case suggests that multidisciplinary treatment with GEM may prolong the survival of some patients with unresectable pancreatic cancer.

show abstract

“…Dans cette é tude, la TEP-FDG a permis d'identifier le primitif pour Tableau 2. Ré sultats rapporté s dans les principales é tudes non ciblé es sur les mé tastases ganglionnaires cervicales La TEP-FDG permet, dans ces é tudes, d'identifier le primitif en moyenne pour 37 % des patients (24 à 100 % en fonction des sé ries [2,9,11,18,[21][22][23][24][25][28][29][30]35]) (Fig. 1).…”

Section: Tep-fdg Et Syndrome Capi Non Ciblé Sur Les Mé Tastases Cerviunclassified

“…La TEP-FDG a conditionné le traitement en moyenne pour 35 % des patients (10 à 69 %) en fonction des sé ries [2,9,18,21,[23][24][25]28,29,35].…”

Section: Tep-fdg Et Syndrome Capi Non Ciblé Sur Les Mé Tastases Cerviunclassified

Usefulness of FDG-PET in the management of carcinoma of unknown primary

Garin

Lesimple

2008

Oncologie

View full text Add to dashboard Cite

FDG-PET has proven to be a valuable diagnostic tool in patients with a carcinoma of unknown primary. In patients presenting with cervical metastases of unknown primary, FDG-PET makes it possible to locate a primary in 36% of the patients and induces therapeutic modification in 39%. This examination should be carried out prior to upper endoscopy, guiding the biopsies when possible. In patients presenting with non-cervical metastases, FDG-PET localize the primary in 37% of cases, with an impact on the therapeutic management in 42% of the patients. Recent results from coupled PET-CT-scanning examinations seem to improve the diagnostic performances this assessment modality, especially its specificity. The prognostic value of FDG-PET still needs to be evaluated.Ré sumé : La TEP-FDG pré sente de façon indiscutable un inté rê t dans la prise en charge des patients pré sentant un syndrome CAPI. Pour les CAPI avec mé tastases cervicales, la TEP-FDG permet de localiser le primitif pour 36 % des patients et entraîne une modification thé rapeutique dans 39 % des cas. La TEP-FDG devrait ê tre ré alisé e avant la pan-endoscopie. Cela permet de diriger les biopsies. Par ailleurs, la ré alisation de la TEP-FDG aprè s la pan-endoscopie augmente fortement le risque de faux positif. Pour les patients qui pré sentent des mé tastases autres que cervicales, la TEP-FDG permet de localiser le primitif en moyenne dans 37 % des cas, de localiser la pré sence d'une extension mé tastatique plus importante chez 42 % des patients et induit une modification thé rapeutique pour 35 % des patients. Dans cette indication, la TEP-FDG semble plus inté ressante dans les formes localisé es que multifocales où l'identification d'un primitif est plus dé licate et l'impact thé rapeutique moins important. L'apparition ré cente des é tudes couplé es TEP-CT semble amé liorer discrè tement la sensibilité de cet examen et surtout en amé liorer significativement la spé cificité . Enfin, l'inté rê t pronostique de la TEP-FDG dans cette caté gorie de patients reste à ê tre pré cisé .

show abstract

The Utility of 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography in the Investigation of Patients with Disseminated Carcinoma of Unknown Primary Origin

Cited by 23 publications

References 19 publications

Clinical implication of 18F-FDG PET/CT in carcinoma of unknown primary

Clinical implication of 18F-FDG PET/CT in carcinoma of unknown primary

Successful Resection of Advanced Pancreatic Tail Cancer After Neoadjuvant Gemcitabine Chemotherapy: Report of a Case

Usefulness of FDG-PET in the management of carcinoma of unknown primary

Contact Info

Product

Resources

About